Coherus Oncology, Inc.
A biopharmaceutical company that develops and sells immuno-oncology medicines — therapies that help the immune system find and attack cancer cells. Its flagship product, LOQTORZI, is an FDA-approved treatment for nasopharyngeal carcinoma, a type of head and neck cancer. Founded in 2010 by a longtime Amgen executive, the company spent over a decade as a maker of lower-cost biosimilar drugs before selling those products and renaming itself Coherus Oncology in 2025 to focus purely on cancer treatments. The name "Coherus" evokes the word "cohere," reflecting the company's focus on combining different therapies to fight cancer.
1.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
4.01 Changes in Registrant's Certifying Accountant · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits